Literature DB >> 18401567

C-reactive protein gene polymorphisms affect plasma CRP and homocysteine concentrations in subjects with and without angiographically confirmed coronary artery disease.

Daria Pasalić1, Natalija Marinković, Branka Grsković, Goran Ferencak, Robert Bernat, Ana Stavljenić-Rukavina.   

Abstract

Human C-reactive protein (CRP) is a reactant involved in the acute phase response and one of the many molecular factors involved in pathogenesis of coronary artery disease (CAD). CRP gene variants potentially mediate CRP plasma concentrations and the development of CAD. 220 Croatian subjects with angiographically confirmed CAD and 132 control subjects were included in the study. CRP gene polymorphisms 1059G/C and -717G/A were determined by RFLPs, using MaeIII and KspI endonuclease, respectively. Plasma concentrations of CRP and homocysteine were determined by immunoturbidimetry and FPIA, respectively. CRP 1059G/C gene variants were significantly associated with CAD (OR = 0.50; 95% CI = 0.27, 0.94; P = 0.032). Wild GG genotype and rare allele C carrier genotypes were 184 and 22 in CAD(+) group, and 101 and 24 in CAD(-) group, respectively. Multivariate analysis with age, gender, BMI, smoking status, hypertension and diabetes as covariates showed that 1059C carriers had lower CRP concentrations in CAD(-) (P = 0.010) and CAD(+) subjects (P = 0.028). This allele was also significantly associated with lower plasma homocysteine concentrations in both groups (P = 0.018 for CAD(-) and 0.002 for CAD(+). There was no significant difference between CAD(+) and CAD(-) subjects in absolute frequencies for CRP -717A/G gene variant, but multivariate analysis showed that carriers of the rarer G allele had significantly higher CRP plasma concentrations in CAD(-) subjects (P = 0.031) and higher homocysteine concentrations in CAD(+) group (P < 0.001). Atherosclerosis is an inflammatory disease resulting from different genetic and environmental factors. Results presented here support the contribution of CRP genetic variations in the development of CAD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401567     DOI: 10.1007/s11033-008-9244-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  30 in total

Review 1.  C-reactive protein and cardiovascular disease: a review of risk prediction and interventions.

Authors:  Sarah de Ferranti; Nader Rifai
Journal:  Clin Chim Acta       Date:  2002-03       Impact factor: 3.786

2.  Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C.

Authors:  G Wang; Y L Siow; K O
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

3.  Human C-reactive protein (CRP) 1059G/C polymorphism.

Authors:  H Cao; R A Hegele
Journal:  J Hum Genet       Date:  2000       Impact factor: 3.172

Review 4.  Airway smooth muscle cell as therapeutic target of inflammation.

Authors:  Chi-Ming Hai
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 5.  Biochemistry of homocysteine in health and diseases.

Authors:  S Ramakrishnan; K N Sulochana; S Lakshmi; R Selvi; N Angayarkanni
Journal:  Indian J Biochem Biophys       Date:  2006-10       Impact factor: 1.918

6.  A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein.

Authors:  Alexander Kovacs; Fiona Green; Lars-Olof Hansson; Pia Lundman; Ann Samnegård; Susanna Boquist; Carl-Göran Ericsson; Hugh Watkins; Anders Hamsten; Per Tornvall
Journal:  Atherosclerosis       Date:  2005-01       Impact factor: 5.162

7.  Epistatic effect of C-reactive protein (CRP) single nucleotide polymorphism (SNP) +1059 and interleukin-1B SNP +3954 on CRP concentration in healthy male blood donors.

Authors:  C Eklund; T Lehtimäki; M Hurme
Journal:  Int J Immunogenet       Date:  2005-08       Impact factor: 1.466

8.  C-reactive protein gene polymorphisms and the incidence of post-angioplasty restenosis.

Authors:  Robert Y L Zee; Hillary H Hegener; Arturo Fernandez-Cruz; Klaus Lindpaintner
Journal:  Atherosclerosis       Date:  2004-10       Impact factor: 5.162

9.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

10.  C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.

Authors:  Jian-Jun Li; Chun-Hong Fang
Journal:  Med Hypotheses       Date:  2004       Impact factor: 1.538

View more
  12 in total

1.  C-reactive protein (CRP) gene polymorphisms: implication in CRP plasma levels and susceptibility to acute myocardial infarction.

Authors:  Reza Akbarzadeh Najar; Sayyed Mohammad Hossein Ghaderian; Akram Sadat Tabatabaei Panah
Journal:  Mol Biol Rep       Date:  2011-07-01       Impact factor: 2.316

2.  A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.

Authors:  Lian-Sheng Wang; Jian-Jun Yan; Na-Ping Tang; Jun Zhu; Yue-Song Wang; Qi-Ming Wang; Jian-Jin Tang; Ming-Wei Wang; En-Zhi Jia; Zhi-Jian Yang; Jun Huang
Journal:  Mol Biol Rep       Date:  2010-04-11       Impact factor: 2.316

3.  Relationship between CRP polymorphism and cardiovascular events in Chinese peritoneal dialysis patients.

Authors:  Peter Yam-Kau Poon; Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Kai-Ming Chow; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 8.237

4.  Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.

Authors:  Arzu Ergen; Selim İsbir; Özlem Timirci; Atike Tekeli; Turgay İsbir
Journal:  Mol Biol Rep       Date:  2010-06-22       Impact factor: 2.316

5.  Matrix metalloproteinase-9 functional promoter polymorphism 1562C>T increased risk of early-onset coronary artery disease.

Authors:  Massoud Saedi; Asad Vaisi-Raygani; Shahnaz Khaghani; Ahmad Shariftabrizi; M Rezaie; Parvin Pasalar; Zohreh Rahimi; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2011-05-11       Impact factor: 2.316

6.  Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population.

Authors:  Fang Liu; Zhiyi He; Shumin Deng; Hui Zhang; Nan Li; Jialiang Xu
Journal:  Mol Biol Rep       Date:  2010-09-17       Impact factor: 2.316

7.  A novel haplotype within C-reactive protein gene influences CRP levels and coronary heart disease risk in Northwest Indians.

Authors:  Puneetpal Singh; Monica Singh; Harinder Singh Nagpal; Taranpal Kaur; Shallu Khullar; Gurpreet Kaur; Harjot Dhillon; Mario Di Napoli; Sarabjit Mastana
Journal:  Mol Biol Rep       Date:  2014-06-26       Impact factor: 2.316

8.  CRP gene polymorphism contributes genetic susceptibility to dyslipidemia in Han Chinese population.

Authors:  Wenbin Wei; Song Yang; Yingru Qiu; Hairu Wang; Xianghai Zhao; Yanping Zhao; Yun Li; Ming Wu; Yanchun Chen; Wen Wang; Xiaoming Shi; Sijun Liu; Jinfeng Chen; Hongbing Shen; David Zhao; Yanru Su; Chong Shen; Ying-Shui Yao
Journal:  Mol Biol Rep       Date:  2014-01-29       Impact factor: 2.316

9.  The role of gene variants of the inflammatory markers CRP and TNF-α in cardiovascular heart disease: systematic review and meta-analysis.

Authors:  Yazmín Hernández-Díaz; Carlos Alfonso Tovilla-Zárate; Isela Juárez-Rojop; Manuel Alfonso Baños-González; Manuel Eduardo Torres-Hernández; María Lilia López-Narváez; Teresa Guadalupe Yañez-Rivera; Thelma Beatriz González-Castro
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  C-reactive protein + 1059 G>C polymorphism in type 2 diabetes and coronary artery disease patients.

Authors:  Ramandeep Kaur; Kawaljit Matharoo; Rubina Sharma; A J S Bhanwer
Journal:  Meta Gene       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.